AZOLES, ALLYLAMINES AND DRUG-METABOLISM

被引:50
作者
BACK, DJ
TJIA, JF
ABEL, SM
机构
[1] Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool
关键词
D O I
10.1111/j.1365-2133.1992.tb00003.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Four antifungal drugs, the azoles ketoconazole, itraconazole and fluconazole, and the allylamine terbinafine, were studied for their effects on the metabolism of cyclosporin A (CyA) and cortisol by human liver microsomes in vitro (n=3). Ketoconazole produced marked inhibition of CyA hydroxylase (to metabolites M17 and M1) with IC50 and K(i) values of 0.24 +/- 0.01 and 0.022 +/0. 004-mu-M, respectively. On the basis of the IC50, itraconazole was 10 times less potent (IC50 of 2.2 +/- 0.2-mu-M), and fluconazole and terbinafine were each above 100-mu-M. No kinetic parameters were calculated for terbinafine because of the lack of inhibitory effects. Ketoconazole was the most potent inhibitor of cortisol metabolism (to 6-beta-hydroxycortisol, IC50 = 0.6-mu-M). Itraconazole produced marked inhibition of cortisol metabolism (IC50 = 2.4-mu-M), but fluconazole and terbinafine had little effect. These data confirm that ketoconazole is a potent inhibitor of cytochrome P-450-IIIA4, and this has clinical relevance. Although the inhibition with fluconazole was much less than with itraconazole at equimolar concentrations, it should be noted that in-vivo plasma concentrations of fluconazole are much greater than that of itraconazole. Clinical interactions of CyA with both fluconazole and itraconazole have been reported; in contrast to these azoles, terbinafine does not have the same interaction potential.
引用
收藏
页码:14 / 18
页数:5
相关论文
共 29 条
  • [1] ABEL SM, 1992, IN PRESS BR J CLIN P
  • [2] COMPARATIVE EFFECTS OF 2 ANTIMYCOTIC AGENTS, KETOCONAZOLE AND TERBINAFINE ON THE METABOLISM OF TOLBUTAMIDE, ETHINYLESTRADIOL, CYCLOSPORINE AND ETHOXYCOUMARIN BY HUMAN-LIVER MICROSOMES INVITRO
    BACK, DJ
    STEVENSON, P
    TJIA, JF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (02) : 166 - 170
  • [3] INHIBITION OF THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES BY FK506
    BURKE, MD
    OMAR, G
    THOMSON, AW
    WHITING, PH
    [J]. TRANSPLANTATION, 1990, 50 (05) : 901 - 902
  • [4] COCKBURN I, 1986, TRANSPLANT P, V18, P50
  • [5] DIEPERINK H, 1982, LANCET, V2, P1217
  • [6] FERGUSON RM, 1982, LANCET, V2, P882
  • [7] FIRST MR, 1989, LANCET, V2, P1198, DOI 10.1016/S0140-6736(89)91802-3
  • [8] CYCLOSPORINE DOSE REDUCTION BY KETOCONAZOLE ADMINISTRATION IN RENAL-TRANSPLANT RECIPIENTS
    FIRST, MR
    SCHROEDER, TJ
    ALEXANDER, JW
    STEPHENS, GW
    WEISKITTEL, P
    MYRE, SA
    PESCE, AJ
    [J]. TRANSPLANTATION, 1991, 51 (02) : 365 - 370
  • [9] CONCOMITANT CYCLOSPORINE AND KETOCONAZOLE
    FREY, FJ
    [J]. LANCET, 1990, 335 (8681) : 109 - 110
  • [10] THE INCREASE IN URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL AS A MARKER OF HUMAN HEPATIC CYTOCHROME-P450IIIA INDUCTION
    GED, C
    ROUILLON, JM
    PICHARD, L
    COMBALBERT, J
    BRESSOT, N
    BORIES, P
    MICHEL, H
    BEAUNE, P
    MAUREL, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) : 373 - 387